Church & Dwight (CHD) 10-Q 28 Oct 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Oct. 26, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Trading Symbol	CHD
Entity Registrant Name	CHURCH & DWIGHT CO., INC.
Entity Central Index Key	0000313927
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	1-10585
Entity Tax Identification Number	13-4996950
Entity Address, Address Line One	500 Charles Ewing Boulevard
Entity Address, City or Town	Ewing
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08628
City Area Code	609
Local Phone Number	806-1200
Entity Incorporation, State or Country Code	DE
Title of 12(b) Security	Common Stock, $1 par value
Security Exchange Name	NYSE
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding		243,868,347

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Net Sales	$ 1,317.3	$ 1,311.4	$ 3,939.6	$ 3,821.4
Cost of sales	767.6	732.2	2,292.1	2,139.1
Gross Profit	549.7	579.2	1,647.5	1,682.3
Marketing expenses	140.7	160.9	345.5	376.6
Selling, general and administrative expenses	155.1	116.9	505.8	403
Income from Operations	253.9	301.4	796.2	902.7
Equity in earnings of affiliates	3.7	2	10	7.4
Investment earnings, net	1.5	0	1.8	0.1
Other income (expense), net	(0.9)	(0.7)	(1.2)	(1.1)
Interest expense	(23.7)	(13.4)	(59.6)	(41.5)
Income before Income Taxes	234.5	289.3	747.2	867.6
Income taxes	47.4	58.9	168.6	198.2
Net Income	$ 187.1	$ 230.4	$ 578.6	$ 669.4
Weighted average shares outstanding - Basic	242.8	245.3	242.7	245.2
Weighted average shares outstanding - Diluted	246	249.8	246.4	249.9
Net income per share - Basic	$ 0.77	$ 0.94	$ 2.38	$ 2.73
Net income per share - Diluted	0.76	0.92	2.35	2.68
Cash dividends per share	$ 0.26	$ 0.25	$ 0.79	$ 0.76

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net Income	$ 187.1	$ 230.4	$ 578.6	$ 669.4
Other comprehensive income, net of tax:
Foreign exchange translation adjustments	(13.3)	(5.1)	(27.8)	(4.7)
Defined benefit plan adjustments gain (loss)	0	0	1.9	(0.7)
Income (loss) from derivative agreements	14.3	10	48	22.1
Other comprehensive income (loss)	1	4.9	22.1	16.7
Comprehensive income	$ 188.1	$ 235.3	$ 600.7	$ 686.1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 437.6	$ 240.6
Accounts receivable, less allowances of $4.0 and $5.5	391.3	405.5
Inventories	675.3	535.4
Other current assets	60.2	51.9
Total Current Assets	1,564.4	1,233.4
Property, Plant and Equipment, Net	716.3	652.7
Equity Investment in Affiliates	11.9	9.1
Trade Names and Other Intangibles, Net	3,404.1	3,494.3
Goodwill	2,270.7	2,274.5
Other Assets	320.4	332.5
Total Assets	8,287.8	7,996.5
Current Liabilities
Short-term borrowings	3.3	252.8
Current portion of long-term debt	400	699.4
Accounts payable and accrued expenses	1,032	1,119.7
Income taxes payable	15.3	3.3
Total Current Liabilities	1,450.6	2,075.2
Long-term Debt	2,104.4	1,610.7
Deferred Income Taxes	738.9	745.1
Deferred and Other Long-term Liabilities	272.1	298.3
Business Acquisition Liabilities	34	34
Total Liabilities	4,600	4,763.3
Commitments and Contingencies
Stockholders' Equity
Preferred Stock, $1.00 par value, Authorized 2,500,000 shares; none issued	0	0
Common Stock, $1.00 par value, Authorized 600,000,000 shares and 292,855,100 shares issued as of September 30, 2022 and December 31, 2021	292.8	292.8
Additional paid-in capital	355.9	310.3
Retained earnings	5,753.4	5,366
Accumulated other comprehensive loss	(46.1)	(68.2)
Common stock in treasury, at cost: 49,896,366 shares as of September 30, 2022 and 50,309,124 shares as of December 31, 2021	(2,668.2)	(2,667.7)
Total Stockholders' Equity	3,687.8	3,233.2
Total Liabilities and Stockholders' Equity	$ 8,287.8	$ 7,996.5

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Accounts receivable, allowances	$ 4	$ 5.5
Preferred Stock, par value	$ 1	$ 1
Preferred Stock, Authorized	2,500,000	2,500,000
Preferred Stock, issued	0	0
Common Stock, par value	$ 1	$ 1
Common Stock, Authorized	600,000,000	600,000,000
Common Stock, shares issued	292,855,100	292,855,100
Common stock in treasury, shares	49,896,366	50,309,124

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flow From Operating Activities
Net Income	$ 578.6	$ 669.4
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation expense	50.1	51.3
Amortization expense	110.5	113.6
Change in fair value of business acquisition liabilities	0	(98)
Deferred income taxes	(12.7)	32.8
Equity in net earnings of affiliates	(10)	(7.4)
Distributions from unconsolidated affiliates	7.2	7.5
Non-cash compensation expense	22	20.3
Other	(1.5)	5.8
Change in assets and liabilities:
Accounts receivable	(1.7)	(12)
Inventories	(152.7)	(59.9)
Other current assets	4.7	6.1
Accounts payable and accrued expenses	(56)	(50.8)
Income taxes payable	16.5	(10.3)
Other operating assets and liabilities, net	(20.9)	(14.8)
Net Cash Provided By Operating Activities	534.1	653.6
Cash Flow From Investing Activities
Additions to property, plant and equipment	(98.1)	(64.1)
Other	(2.6)	(5.6)
Net Cash Used In Investing Activities	(100.7)	(69.7)
Cash Flow From Financing Activities
Long Term debt borrowings	499.8	0
Long-term debt (repayments)	(300)	(300)
Short-term debt (repayments), net of borrowings	(249.5)	(71.6)
Proceeds from stock options exercised	22.4	26.9
Payment of cash dividends	(191.2)	(185.8)
Purchase of treasury stock	0	(54.9)
Deferred financing and other	(7.5)	0
Net Cash Provided By (Used In) Financing Activities	(226)	(585.4)
Effect of exchange rate changes on cash and cash equivalents	(10.4)	(1.6)
Net Change In Cash and Cash Equivalents	197	(3.1)
Cash and Cash Equivalents at Beginning of Period	240.6	183.1
Cash and Cash Equivalents at End of Period	437.6	180
Cash paid during the period for:
Interest (net of amounts capitalized)	54	45.4
Income taxes	165.5	175.7
Supplemental disclosure of non-cash investing activities:
Property, plant and equipment expenditures included in Accounts Payable	$ 34.4	$ 11.2

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Millions	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
Beginning Balance at Dec. 31, 2020	$ 3,020.4	$ 292.8	$ (2,255.2)	$ 274.4	$ 4,786	$ (77.6)
Beginning Balance (in shares) at Dec. 31, 2020		292.8	(47.4)
Net income	220.7	$ 0	$ 0	0	220.7	0
Other comprehensive income (loss)	23	0	0	0	0	23
Cash dividends	(61.9)	0	0	0	(61.9)	0
Stock purchases	0	$ 0	$ (30)	30	0	0
Stock purchases (in shares)		0	(0.4)
Stock based compensation expense and stock option plan transactions	9	$ 0	$ 7.2	1.8	0	0
Stock based compensation expense and stock option plan transactions (in shares)		0	0.1
Ending Balance at Mar. 31, 2021	3,211.2	$ 292.8	$ (2,278)	306.2	4,944.8	(54.6)
Ending Balance (in shares) at Mar. 31, 2021		292.8	(47.7)
Beginning Balance at Dec. 31, 2020	3,020.4	$ 292.8	$ (2,255.2)	274.4	4,786	(77.6)
Beginning Balance (in shares) at Dec. 31, 2020		292.8	(47.4)
Net income	669.4
Other comprehensive income (loss)	16.7
Ending Balance at Sep. 30, 2021	3,513.6	$ 292.8	$ (2,315.8)	327.9	5,269.6	(60.9)
Ending Balance (in shares) at Sep. 30, 2021		292.8	(47.9)
Beginning Balance at Mar. 31, 2021	3,211.2	$ 292.8	$ (2,278)	306.2	4,944.8	(54.6)
Beginning Balance (in shares) at Mar. 31, 2021		292.8	(47.7)
Net income	218.3	$ 0	$ 0	0	218.3	0
Other comprehensive income (loss)	(11.2)	0	0	0	0	(11.2)
Cash dividends	(61.9)	0	0	0	(61.9)	0
Stock based compensation expense and stock option plan transactions	20.8	$ 0	$ 6.5	14.3	0	0
Stock based compensation expense and stock option plan transactions (in shares)		0	0.2
Ending Balance at Jun. 30, 2021	3,377.2	$ 292.8	$ (2,271.5)	320.5	5,101.2	(65.8)
Ending Balance (in shares) at Jun. 30, 2021		292.8	(47.5)
Net income	230.4	$ 0	$ 0	0	230.4	0
Other comprehensive income (loss)	4.9	0	0	0	0	4.9
Cash dividends	(62)	0	0	0	(62)	0
Stock purchases	(54.9)	$ 0	$ (54.9)	0	0	0
Stock purchases (in shares)		0	(0.7)
Stock based compensation expense and stock option plan transactions	18	$ 0	$ 10.6	7.4	0	0
Stock based compensation expense and stock option plan transactions (in shares)		0	0.3
Ending Balance at Sep. 30, 2021	3,513.6	$ 292.8	$ (2,315.8)	327.9	5,269.6	(60.9)
Ending Balance (in shares) at Sep. 30, 2021		292.8	(47.9)
Beginning Balance at Dec. 31, 2021	3,233.2	$ 292.8	$ (2,667.7)	310.3	5,366	(68.2)
Beginning Balance (in shares) at Dec. 31, 2021		292.8	(50.3)
Net income	204.4	$ 0	$ 0	0	204.4	0
Other comprehensive income (loss)	15	0	0	0	0	15
Cash dividends	(63.7)	0	0	0	(63.7)	0
Stock purchases	0	$ 0	$ (20)	20	0	0
Stock purchases (in shares)		0	(0.2)
Stock based compensation expense and stock option plan transactions	14	$ 0	$ 10.1	3.9	0	0
Stock based compensation expense and stock option plan transactions (in shares)		0	0.3
Ending Balance at Mar. 31, 2022	3,402.9	$ 292.8	$ (2,677.6)	334.2	5,506.7	(53.2)
Ending Balance (in shares) at Mar. 31, 2022		292.8	(50.2)
Beginning Balance at Dec. 31, 2021	3,233.2	$ 292.8	$ (2,667.7)	310.3	5,366	(68.2)
Beginning Balance (in shares) at Dec. 31, 2021		292.8	(50.3)
Net income	578.6
Other comprehensive income (loss)	22.1
Ending Balance at Sep. 30, 2022	3,687.8	$ 292.8	$ (2,668.2)	355.9	5,753.4	(46.1)
Ending Balance (in shares) at Sep. 30, 2022		292.8	(49.9)
Beginning Balance at Mar. 31, 2022	3,402.9	$ 292.8	$ (2,677.6)	334.2	5,506.7	(53.2)
Beginning Balance (in shares) at Mar. 31, 2022		292.8	(50.2)
Net income	187.1	$ 0	$ 0	0	187.1	0
Other comprehensive income (loss)	6.1	0	0	0	0	6.1
Cash dividends	(63.7)	0	0	0	(63.7)	0
Stock based compensation expense and stock option plan transactions	22	$ 0	$ 6.1	15.9	0	0
Stock based compensation expense and stock option plan transactions (in shares)		0	0.2
Ending Balance at Jun. 30, 2022	3,554.4	$ 292.8	$ (2,671.5)	350.1	5,630.1	(47.1)
Ending Balance (in shares) at Jun. 30, 2022		292.8	(50)
Net income	187.1	$ 0	$ 0	0	187.1	0
Other comprehensive income (loss)	1	0	0	0	0	1
Cash dividends	(63.8)	0	0	0	(63.8)	0
Stock based compensation expense and stock option plan transactions	9.1	$ 0	$ 3.3	5.8	0	0
Stock based compensation expense and stock option plan transactions (in shares)		0	0.1
Ending Balance at Sep. 30, 2022	$ 3,687.8	$ 292.8	$ (2,668.2)	$ 355.9	$ 5,753.4	$ (46.1)
Ending Balance (in shares) at Sep. 30, 2022		292.8	(49.9)

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation These condensed consolidated financial statements have been prepared by Church & Dwight Co., Inc. (the “Company”). In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position and results of operations and cash flows for all periods presented have been made. Results of operations for interim periods may not be representative of results to be expected for the full year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”). The Company incurred research and development expenses in the third quarter of 2022 and 2021 of $ 29.2 and $ 27.7 , respectively. The Company incurred research and development expenses in the first nine months of 2022 and 2021 of $ 80.9 and $ 77.2 , respectively. These expenses are included in selling, general and administrative (“SG&A”) expenses.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Sep. 30, 2022
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	2. New Accounting Pronouncements Recently Adopted Accounting Pronouncements In March 2020, the FASB issued new accounting guidance intended to provide temporary optional expedients and exceptions to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (“LIBOR”) and other interbank offered rates to alternative reference rates. This guidance was effective beginning on March 12, 2020, and the Company may apply the amendments prospectively to contract modifications made or relationships entered into or evaluated through December 31, 2022. The adoption of this guidance did not have an impact on the Company’s consolidated financial position, results of operations or cash flows in the current period. The Company will continue to evaluate the impacts of this guidance on future contracts through December 31, 2022. Recent Accounting Pronouncements Not Yet Adopted In September 2022, the FASB issued new accounting guidance intended to add certain qualitative and quantitative disclosure requirements for a buyer in a supplier finance program. The amendments require a buyer that uses supplier finance programs to make annual disclosures about the program’s key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period, and associated rollforward information. Only the amount outstanding at the end of the period must be disclosed in interim periods. The amendments are effective for all entities for fiscal years beginning after December 15, 2022 on a retrospective basis, including interim periods within those fiscal years, except for the requirement to disclose rollforward information, which is effective prospectively for fiscal years beginning after December 15, 2023. The Company is currently evaluating the impact of adoption, which is expected to result in additional disclosures in 2023. There have been no other accounting pronouncements issued but not yet adopted by the Company which are expected to have a material impact on the Company’s consolidated financial position, results of operations or cash flows.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventories	3. Inventories Inventories consist of the following: September 30, December 31, 2022 2021 Raw materials and supplies $ 145.1 $ 116.2 Work in process 51.6 40.0 Finished goods 478.6 379.2 Total $ 675.3 $ 535.4

Property, Plant and Equipment,

Property, Plant and Equipment, Net ("PP&E")	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net ("PP&E")	4. Property, Plant and Equipment, Net (“PP&E”) PP&E consists of the following: September 30, December 31, 2022 2021 Land $ 28.1 $ 28.3 Buildings and improvements 292.2 290.8 Machinery and equipment 851.9 828.9 Software 110.6 107.8 Office equipment and other assets 93.8 92.7 Construction in progress 175.7 104.3 Gross PP&E 1,552.3 1,452.8 Less accumulated depreciation and amortization 836.0 800.1 Net PP&E $ 716.3 $ 652.7 Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Depreciation expense on PP&E $ 16.7 $ 17.2 $ 50.1 $ 51.3

Earnings Per Share ("EPS")

Earnings Per Share ("EPS")	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Earnings Per Share ("EPS")	5. Earnings Per Share (“EPS”) Basic EPS is calculated based on income available to holders of the Company’s common stock (“Common Stock”) and the weighted average number of shares outstanding during the reported period. Diluted EPS includes additional dilution from potential Common Stock issuable pursuant to the exercise of outstanding stock options. The following table sets forth a reconciliation of the weighted average number of shares of Common Stock outstanding to the weighted average number of shares outstanding on a diluted basis: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Weighted average common shares outstanding - basic 242.8 245.3 242.7 245.2 Dilutive effect of stock options 3.2 4.5 3.7 4.7 Weighted average common shares outstanding - diluted 246.0 249.8 246.4 249.9 Antidilutive stock options outstanding 3.0 1.6 3.0 1.6

Stock Based Compensation Plans

Stock Based Compensation Plans	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock Based Compensation Plans	6. Stock Based Compensation Plans The following table provides a summary of option activity: Weighted Average Weighted Remaining Average Contractual Aggregate Exercise Term Intrinsic Options Price (in Years) Value Outstanding at December 31, 2021 11.3 $ 58.83 Granted 1.5 85.21 Exercised ( 0.6 ) 40.81 Cancelled ( 0.3 ) 78.76 Outstanding at September 30, 2022 11.9 $ 62.53 5.9 $ 159.0 Exercisable at September 30, 2022 7.3 $ 50.77 4.2 $ 159.0 The following table provides information regarding the intrinsic value of stock options exercised and stock compensation expense related to stock option awards: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Intrinsic Value of Stock Options Exercised $ 3.3 $ 12.0 $ 29.6 $ 30.8 Stock Compensation Expense Related to Stock Option Awards $ 4.1 $ 3.4 $ 21.6 $ 19.9 Issued Stock Options 0.0 0.0 1.5 1.5 Weighted Average Fair Value of Stock Options issued (per share) $ 0.0 $ 0.0 $ 21.48 $ 17.33 Fair Value of Stock Options Issued $ 0.0 $ 0.0 $ 32.7 $ 26.1 The following table provides a summary of the assumptions used in the valuation of issued stock options: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Risk-free interest rate - - 2.9 % 1.3 % Expected life in years - - 7.1 7.2 Expected volatility - - 21.7 % 20.7 % Dividend yield - - 1.2 % 1.2 %

Share Repurchases

Share Repurchases	9 Months Ended
	Sep. 30, 2022
Payments for Repurchase of Equity [Abstract]
Share Repurchases	7. Share Repurchases On October 28, 2021, the Board authorized a new share repurchase program, under which the Company may repurchase up to $ 1,000.0 in shares of Common Stock (the “2021 Share Repurchase Program”). The 2021 Share Repurchase Program does not have an expiration and replaced the 2017 Share Repurchase Program. All remaining dollars authorized for repurchase under the 2017 Share Repurchase Plan have been cancelled. The 2021 Share Repurchase Program did not modify the Company’s evergreen share repurchase program, authorized by the Board on January 29, 2014, under which the Company may repurchase, from time to time, Common Stock to reduce or eliminate dilution associated with issuances of Common Stock under its incentive plans. In December 2021, the Company executed open market purchases of 1.8 million shares for $ 170.3 , inclusive of fees, of which $ 100.0 was purchased under the evergreen share repurchase program and $ 70.3 was purchased under the 2021 Share Repurchase Program. In December 2021, the Company also entered into an accelerated share repurchase contract ("ASR") with a commercial bank to purchase Common Stock. The Company paid $ 200.0 to the bank, inclusive of fees, and received an initial delivery of shares equal to $ 180.0 , or 1.8 million shares. The Company used cash on hand and short-term borrowings to fund the initial purchase price. Upon the completion of the ASR, which ended in February 2022, the bank delivered an additional 0.2 million shares to the Company. The final shares delivered to the Company were determined by the average price per share paid by the bank during the purchase period. All 2.0 million shares were purchased under the 2021 Share Repurchase Program . As a result of the Company’s recent stock repurchases, there remains $ 729.7 of share repurchase availability under the 2021 Share Repurchase Program as of September 30, 2022 .

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	8. Fair Value Measurements The following table provides the carrying amounts and estimated fair values of the Company’s financial instruments at September 30, 2022 and December 31, 2021: September 30, 2022 December 31, 2021 Input Carrying Fair Carrying Fair Level Amount Value Amount Value Financial Assets: Cash equivalents Level 1 $ 192.0 $ 192.0 $ 17.1 $ 17.1 Financial Liabilities: Short-term borrowings Level 2 3.3 3.3 252.8 252.8 2.45 % Senior notes due August 1, 2022 Level 2 0.0 0.0 300.0 302.9 2.875 % Senior notes due October 1, 2022 Level 2 400.0 400.0 399.9 406.4 Term loan due December 22, 2024 Level 2 400.0 400.0 400.0 400.0 3.15 % Senior notes due August 1, 2027 Level 2 424.8 387.7 424.7 450.1 2.3 % Senior notes due December 15, 2031 Level 2 399.2 313.2 399.2 403.5 3.95 % Senior notes due August 1, 2047 Level 2 397.6 313.5 397.5 471.6 5.00 % Senior notes due June 15, 2052 Level 2 499.8 458.3 0.0 0.0 Interest Rate Lock Agreement (asset) liability Level 2 ( 12.5 ) ( 12.5 ) 41.6 41.6 Business Acquisition Liabilities Level 3 34.0 34.0 34.0 34.0 The Company recognizes transfers between input levels as of the actual date of the event. There were no transfers between input levels during the nine months ended September 30, 2022. Refer to Note 2 in the Form 10-K for a description of the methods and assumptions used to estimate the fair value of each class of financial instruments reflected in the condensed consolidated balance sheets. The business acquisition liabilities represent the estimated fair value of additional future contingent consideration payable for acquisitions of businesses that included contingent consideration clauses. The fair value of business acquisition liabilities is evaluated on an ongoing basis and is based on management estimates and entity-specific assumptions which are considered Level 3 inputs. As of both September 30, 2022 and December 31, 2021, the Company had a business acquisition liability of $ 20.0 in connection with the Zicam Acquisition and a $ 14.0 business acquisition liability in connection with the TheraBreath Acquisition (b oth of which are defined in Note 10). Any amount that may be due for the Zicam business acquisition liability is payable five years from the closing date. Any amount that may be due for the TheraBreath business acquisition liability is payable in installments between two and four years from the closing . The interest rate lock agreements outstanding as of December 31, 2021 were used to hedge the risk of changes in the interest payments associated with the 5.0% Senior Notes due June 15, 2052. These agreements were settled in the second quarter of 2022 for a loss of $ 4.2 , which will be amortized into interest expense over ten years . The Company has entered into additional interest rate lock agreements in the third quarter of 2022 which are used to hedge the risk of changes in the interest payments associated with the anticipated issuance of debt in the fourth quarter of 2022. The carrying amounts of Accounts Receivable, and Accounts Payable and Accrued Expenses, approximated estimated fair values as of September 30, 2022 and December 31, 2021 .

Derivative Instruments and Risk

Derivative Instruments and Risk Management	9 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Risk Management	9. Derivative Instruments and Risk Management Changes in interest rates, foreign exchange rates, the price of the Common Stock and commodity prices expose the Company to market risk. The Company manages these risks by the use of derivative instruments, such as cash flow and fair value hedges, diesel and commodity hedge contracts, equity derivatives and foreign exchange forward contracts. The Company does not use derivatives for trading or speculative purposes. Refer to Note 3 in the Form 10-K for a discussion of each of the Company’s derivative instruments in effect as of December 31, 2021. The notional amount of a derivative instrument is the nominal or face amount used to calculate payments made on that instrument. Notional amounts are presented in the following table: Notional Notional Amount Amount September 30, 2022 December 31, 2021 Derivatives designated as hedging instruments Foreign exchange contracts $ 219.9 $ 216.3 Interest rate lock agreements $ 500.0 $ 300.0 Diesel fuel contracts 3.9 gallons 0.0 gallons Commodities contracts 8.6 pounds 72.1 pounds Derivatives not designated as hedging instruments Foreign exchange contracts $ 5.9 $ 5.9 Equity derivatives $ 23.8 $ 28.9 Excluding the interest rate lock agreements, the fair values and amount of gain (loss) recognized in income and Other Comprehensive Income (“OCI”) associated with the derivative instruments disclosed above did not have a material impact on the Company’s condensed consolidated financial statements during the three and nine months ended September 30, 2022. The interest rate lock agreements outstanding at December 31, 2021 were settled in the second quarter of 2022 for a loss of $ 4.2 , which will be amortized into interest expense over ten years . The Company has entered into additional interest rate lock agreements in the third quarter of 2022 which are used to hedge the risk of changes in the interest payments associated with the anticipated issuance of debt in the fourth quarter of 2022.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2022
Business Combinations [Abstract]
Acquisitions	10. Acquisitions On December 24, 2021, the Company acquired all of the outstanding equity of Dr. Harold Katz, LLC and HK-IP International, Inc. , the owners of the THERABREATH® brand of oral care products business (the “TheraBreath Acquisition”). The Company paid $ 556.0 , net of cash acquired, at closing and deferred an additional cash payment of $ 14.0 related to certain indemnity obligations provided by the seller. The deferred amount is recorded in Business Acquisition Liabilities on the consolidated balance sheet and the additional amount, to the extent not used in satisfaction of such indemnity obligations, is payable in installments between two and four years from the closing. THERABREATH’s annual net sales for the year ended December 31, 2021 were approximately $ 100.0 . The acquisition was financed by the proceeds from a $ 400.0 three-year term loan and the Company’s underwritten public offering of $ 400.0 aggregate principal 2.30% Senior Notes due on December 15, 2031 completed on December 10, 2021. The THERABREATH business is managed in the Consumer Domestic and Consumer International segments. The fair values of the net assets at acquisition are set forth as follows: Accounts receivable $ 11.3 Inventory 12.9 Trade name (indefinite lived) 487.0 Other intangible assets 30.1 Goodwill 39.9 Accounts payable and accrued expenses ( 11.2 ) Business acquisition liabilities - long-term ( 14.0 ) Cash purchase price (net of cash acquired) $ 556.0 The trade names and other intangible assets were valued using a discounted cash flow model. The life of the amortizable intangible assets recognized from the TheraBreath Acquisition have a useful life which ranges from 10 - 20 years. The goodwill is a result of expected synergies from combined operations of the acquired business and the Company. Pro forma results are not presented because the impact of the acquisition was not material to the Company’s consolidated financial results. The goodwill and other intangible assets associated with the TheraBreath Acquisition are deductible for U.S. tax purposes. On December 1, 2020, the Company acquired all of the outstanding equity of Consumer Health Holdco LLC, the owner of the ZICAM® brand and cold remedy products business (the “Zicam Acquisition”). The Company paid $ 512.7 , net of cash acquired, at closing and deferred an additional cash payment of $ 20.0 related to certain indemnifications provided by the seller. The deferred amount is recorded in Business Acquisition Liabilities on the consolidated balance sheet and any amount that may be due for the business acquisition liability is payable five years from the closing. Zicam’s annual net sales for the year ended December 31, 2020 were approximately $ 107.0 . The acquisition was financed by the Company with a combination of cash on hand and short-term borrowings. The ZICAM business is managed in the Consumer Domestic segment. The fair values of the net assets at acquisition are set forth as follows: Inventory and other working capital $ 40.2 Property, plant and equipment 0.5 Trade name 367.8 Other intangible assets 93.8 Goodwill 152.2 Current liabilities ( 13.1 ) Deferred income taxes ( 108.0 ) Long-term liabilities ( 20.7 ) Cash purchase price (net of cash acquired) $ 512.7 The trade names and other intangible assets were valued using a discounted cash flow model. All of the intangible assets recognized from the Zicam Acquisition have a useful life which ranges from 10 - 20 years. The goodwill is a result of expected synergies from combined operations of the acquired business and the Company. Pro forma results are not presented because the impact of the acquisition was not material to the Company’s consolidated financial results. The goodwill and other intangible assets associated with the Zicam Acquisition are not deductible for U.S. tax purposes.

Goodwill and Other Intangibles,

Goodwill and Other Intangibles, Net	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangibles, Net	11. Goodwill and Other Intangibles, Net The following table provides information related to the carrying value of all intangible assets, other than goodwill: September 30, 2022 December 31, 2021 Gross Gross Carrying Accumulated Carrying Accumulated Amount Amortization Net Amount Amortization Net Amortizable intangible assets: Trade Names $ 1,384.7 $ ( 384.5 ) $ 1,000.2 $ 1,386.7 $ ( 336.2 ) $ 1,050.5 Customer Relationships 664.0 ( 349.3 ) 314.7 664.0 ( 322.4 ) 341.6 Patents/Formulas 239.1 ( 110.6 ) 128.5 239.1 ( 99.4 ) 139.7 Total $ 2,287.8 $ ( 844.4 ) $ 1,443.4 $ 2,289.8 $ ( 758.0 ) $ 1,531.8 Indefinite Lived Intangible Assets - Gross Carrying Amount September 30, December 31, 2022 2021 Trade Names $ 1,960.7 $ 1,962.5 Intangible amortization expense was $ 29.3 and $ 29.9 for the third quarter of 2022 and 2021, respectively. Intangible amortization expense amounted to $ 88.1 and $ 90.9 for the first nine months of 2022 and 2021, respectively. The Company estimates that intangible amortization expense will be approximately $ 117.0 in 2022 and approximately $ 115.0 to $ 107.0 annually over the next five years. The Company’s indefinite lived intangible impairment review is completed in the fourth quarter of each year. Fair value for indefinite lived intangible assets was estimated based on a “relief from royalty” or “excess earnings” discounted cash flow method, which contains numerous variables that are subject to change as business conditions change, and therefore could impact fair values in the future. The key assumptions used in determining fair value are sales growth, profitability margins, tax rates, discount rates and royalty rates. The Company determined that the fair value of all indefinite lived intangible assets for each of the years in the three-year period ended December 31, 2021 exceeded their respective carrying values based upon the forecasted cash flows and profitability. Recently, the Company’s global FLAWLESS business has experienced declining customer demand for many of its products, primarily due to lower consumer spending for discretionary products from inflation. In addition, the FLAWLESS business has also started to experience margin contraction as the Company has been unable to implement price increases in a highly competitive category to offset higher labor, material and transportation costs. These factors have resulted in a reduction in expected future cash flows that, if these factors persist or continue to worsen, may result in cash flows that are not sufficient to recover the carrying value of the long-lived assets of the business. The projected cash flows exceed the carrying value of the long lived assets by slightly more than 10 %. The key assumptions used to determine the projected cash flows include revenue, gross margin and marketing expense assumptions based on recent trends, including the reduction in customer demand for discretionary products and declining gross margins that FLAWLESS has been experiencing. The carrying value of the long-lived assets for the FLAWLESS business is approximately $ 465.0 at September 30, 2022. These assets are being amortized over their remaining weighted average life of 16 years. The long-lived assets of the FLAWLESS business are susceptible to impairment risk based on the factors described above. While management can and has implemented strategies to address the risk, including lowerin g the Company’s production costs, investing in new product ideas, and developing new creative advertising, significant adverse changes in demand, operating plans or economic factors in the future could reduce the underlying cash flows that could trigger a future impairment charge. In recent years the Company’s TROJAN® business, specifically the condom category, has not grown and competition has increased. Social distancing requirements due to the COVID-19 pandemic had further negatively impacted the business. As a result, the TROJAN business had experienced stagnant sales and profits resulting in a reduction in expected future cash flows which eroded a portion of the excess between the fair and carrying value of the tradename. This indefinite-lived intangible asset may be susceptible to impairment risk and a continued decline in fair value could trigger a future impairment charge of the TROJAN tradename. The carrying value of the TROJAN tradename is $ 176.4 and fair value exceeded carrying value by 70 % as of October 1, 2021. The key assumptions used in the projections from the Company’s October 1, 2021 impairment analysis include discount rates of 7.0 % in the U.S. and 8.5 % internationally, revenue assumptions based on recent trends, and an average royalty rate of approximately 10 %. While management has implemented strategies to address the risk, including lowering production costs, investing in new product ideas, and developing new creative advertising, significant changes in operating plans or adverse changes in the future could reduce the underlying cash flows used to estimate fair value. More recently, TROJAN has experienced a recovery in sales and profits as it has benefited from an easing of COVID-19 social restrictions which led to an increase in sexual activity. The Company expects this trend will continue with the adoption of vaccines, the reduction of social distancing restrictions and the benefit of management strategies to improve sales and profitability. The Company’s Passport Food Safety business has experienced sales and profit declines due to decreased demand driven by the COVID-19 pandemic and pressures from new competitive activities resulting from the loss of exclusivity on a key product line. In the fourth quarter of 2021, management’s review of the outlook for the Passport business indicated an assessment of the recoverability of the long-lived assets associated with the business was necessary. That review determined that the estimated future cash flows would not be sufficient to recover the carrying value of the assets resulting in an impairment of the associated tradename and other intangible assets of $ 11.3 in the fourth quarter of 2021. The charge was recorded in selling, general and administrative expenses. The assets have a current net book value of approximately $ 8.5 and are being amortized over their remaining weighted average life of 6 years. The Company is implementing strategies to address the decline in profitability. However, if unsuccessful, this decline could trigger an additional future impairment char ge . The carrying amount of goodwill is as follows: Consumer Consumer Specialty Domestic International Products Total Balance at December 31, 2021 $ 1,899.8 $ 238.7 $ 136.0 $ 2,274.5 TheraBreath adjustment 0.5 ( 4.3 ) 0.0 ( 3.8 ) Balance at September 30, 2022 $ 1,900.3 $ 234.4 $ 136.0 $ 2,270.7 The result of the Company’s annual goodwill impairment test, performed in the beginning of the second quarter of 2022, determined that the estimated fair value substantially exceeded the carrying values of all reporting units. The determination of fair value contains numerous variables that are subject to change as business conditions change and therefore could impact fair value in the future. The Company has never incurred a goodwill impairment charge.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	12. Leases The Company leases certain manufacturing facilities, warehouses, office space, railcars and equipment. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet. All recorded leases are classified as operating leases and lease expense is recognized on a straight-line basis over the lease term. For leases beginning in 2019, lease components (base rental costs) are accounted for separately from the nonlease components (e.g., common-area maintenance costs). For leases that do not provide an implicit rate, the Company uses its estimated secured incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. A summary of the Company’s lease information is as follows: September 30, December 31, Classification 2022 2021 Assets Right of use assets Other Assets $ 166.7 $ 159.4 Liabilities Current lease liabilities Accounts Payable and Accrued Expenses $ 22.8 $ 24.4 Long-term lease liabilities Deferred and Other Long-term Liabilities 155.5 146.6 Total lease liabilities $ 178.3 $ 171.0 Other information Weighted-average remaining lease term (years) 9.1 9.1 Weighted-average discount rate 4.4 % 4.3 % Three Months Three Months Nine Months Nine Months Ended Ended Ended Ended September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Statement of Income Lease cost (1) $ 7.7 $ 8.1 $ 23.1 $ 24.6 Other information Leased assets obtained in exchange for new lease liabilities net of modifications (2) $ 9.5 $ 0.4 $ 26.8 $ 4.5 Cash paid for amounts included in the measurement of lease liabilities $ 7.8 $ 8.0 $ 23.3 $ 24.5 (1) Lease expense is included in cost of sales or SG&A expenses based on the nature of the leased item. Short-term lease expense is excluded from this amount and is not material. The Company also has certain variable leases which are not material. The non-cash component of lease expense for the first nine months of 2022 and 2021 was $ 18.0 and $ 19.1 , respectively, and is included in the Amortization caption in the condensed consolidated statement of cash flows. (2) In September 2022, the Company amended its contract at one of its international locations. This resulted in an increase to the Company’s right of use assets and corresponding lease liabilities of approximately $ 8.2 recorded in the third quarter of 2022. In June 2022, the Company amended its contract at one of its leased manufacturing facilities. This resulted in an increase to the Company’s right of use assets and corresponding lease liabilities of approximately $ 15.2 recorded in the second quarter of 2022. The Company’s minimum annual rentals including reasonably assured renewal options under lease agreements are as follows: Operating Leases 2022 $ 8.1 2023 28.6 2024 27.2 2025 26.1 2026 18.7 2027 and thereafter 112.1 Total future minimum lease commitments 220.8 Less: Imputed interest ( 42.5 ) Present value of lease liabilities $ 178.3

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	13. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following: September 30, December 31, 2022 2021 Trade accounts payable $ 655.6 $ 663.8 Accrued marketing and promotion costs 196.3 201.6 Accrued wages and related benefit costs 52.5 87.7 Other accrued current liabilities 127.6 166.6 Total $ 1,032.0 $ 1,119.7

Short-Term Borrowings and Long-

Short-Term Borrowings and Long-Term Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Short-Term Borrowings and Long-Term Debt	14. Short-Term Borrowings and Long-Term Debt Short-term borrowings and long-term debt consist of the following: September 30, December 31, 2022 2021 Short-term borrowings Commercial paper issuances $ 0.0 $ 249.7 Various debt due to international banks 3.3 3.1 Total short-term borrowings $ 3.3 $ 252.8 Long-term debt 2.45 % Senior notes due August 1, 2022 0.0 300.0 2.875 % Senior notes due October 1, 2022 (1) 400.0 400.0 Less: Discount 0.0 ( 0.1 ) Term loan due December 22, 2024 400.0 400.0 3.15 % Senior notes due August 1, 2027 425.0 425.0 Less: Discount ( 0.2 ) ( 0.3 ) 2.3 % Senior notes due December 15, 2031 400.0 400.0 Less: Discount ( 0.8 ) ( 0.8 ) 3.95 % Senior notes due August 1, 2047 400.0 400.0 Less: Discount ( 2.4 ) ( 2.5 ) 5.00 % Senior notes due June 15, 2052 500.0 0.0 Less: Discount ( 0.2 ) 0.0 Debt issuance costs, net ( 17.0 ) ( 11.2 ) Total long-term debt 2,504.4 2,310.1 Less: Current maturities ( 400.0 ) ( 699.4 ) Net long-term debt $ 2,104.4 $ 1,610.7 (1) In October 2022, the Company repaid the full amount of the 2.875 % Senior Notes due October 1, 2022 with a portion of the proceeds from the 5.00 % Senior notes issued on June 2, 2022 and due June 15, 2052 and cash on hand. New Credit Agreement On June 16, 2022, the Company entered into a credit agreement (the “Credit Agreement”) that provides for a $ 1,500.0 unsecured revolving credit facility (the “Revolving Credit Facility”) that matures on June 16, 2027, unless extended. The Credit Agreement replaced the Company’s prior $ 1,000.0 unsecured revolving credit facility maturing on March 29, 2024 that was entered into on March 29, 2018. The Company continues to have the ability to increase its borrowing up to an additional $ 750.0 , subject to lender commitments and certain conditions as described in the Credit Agreement. Borrowings under the Credit Agreement are available for general corporate purposes and are used to support the Company's $ 1,000.0 commercial paper program. 5.00% Senior Notes due June 15, 2052 On June 2, 2022, the Company issued $ 500.0 aggregate principal amount of 5.00 % Senior Notes due 2052 (the “2052 Notes”). The 2052 Notes were issued under the second supplemental indenture (the “Second Supplemental Indenture”), dated June 2, 2022, to the indenture dated December 10, 2021 (the “Indenture”). In July 2022 a portion of the proceeds from the sale of the Notes were used to repay all of the Company's outstanding $ 300.0 2.45 % Senior Notes due August 1, 2022. The remaining proceeds were used to pay a portion of the Company's $ 400.0 outstanding 2.875 % Senior Notes due October 1, 2022. The 2052 Notes will mature on June 15, 2052, unless earlier retired or redeemed pursuant to the terms of the Second Supplemental Indenture.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss)	15. Accumulated Other Comprehensive Income (Loss) The components of changes in accumulated other comprehensive income (loss) are as follows: Accumulated Foreign Defined Other Currency Benefit Derivative Comprehensive Adjustments Plans Agreements Income (Loss) Balance at December 31, 2020 $ ( 26.4 ) $ 0.0 $ ( 51.2 ) $ ( 77.6 ) Other comprehensive income (loss) before reclassifications ( 4.7 ) ( 0.9 ) 32.4 26.8 Amounts reclassified to consolidated statement of (a) (b) 0.0 0.0 ( 2.9 ) ( 2.9 ) Tax benefit (expense) 0.0 0.2 ( 7.4 ) ( 7.2 ) Other comprehensive income (loss) ( 4.7 ) ( 0.7 ) 22.1 16.7 Balance at September 30, 2021 $ ( 31.1 ) $ ( 0.7 ) $ ( 29.1 ) $ ( 60.9 ) Balance at December 31, 2021 $ ( 30.2 ) $ ( 0.6 ) $ ( 37.4 ) $ ( 68.2 ) Other comprehensive income (loss) before reclassifications ( 27.8 ) 2.5 66.1 40.8 Amounts reclassified to consolidated statement of (a) (b) 0.0 0.0 ( 1.2 ) ( 1.2 ) Tax benefit (expense) 0.0 ( 0.6 ) ( 16.9 ) ( 17.5 ) Other comprehensive income (loss) ( 27.8 ) 1.9 48.0 22.1 Balance at September 30, 2022 $ ( 58.0 ) $ 1.3 $ 10.6 $ ( 46.1 ) (a) Amounts reclassified to cost of sales, selling, general and administrative expenses or interest expense. The Company reclassified a gain of $ 0.9 and a gain of $ 2.5 to the condensed consolidated statements of income during the three months ended September 30, 2022 and 2021, respectively.

Commitments, Contingencies and

Commitments, Contingencies and Guarantees	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Guarantees	16. Commitments, Contingencies and Guarantees Commitments a. The Company has a partnership with a supplier of raw materials that mines and processes sodium-based mineral deposits. The Company purchases the majority of its sodium-based raw material requirements from the partnership. The partnership agreement terminates upon two years’ written notice by either partner. Under the partnership agreement, the Company has an annual commitment to purchase 240,000 tons of sodium-based raw materials at the prevailing market price. The Company is not engaged in any other material transactions with the partnership or the partner supplier. b. As of September 30, 2022 , the Company had commitments of approximately $ 314.1 . These commitments include the purchase of raw materials, packaging supplies and services from its vendors at market prices to enable the Company to respond quickly to changes in customer orders or requirements, as well as costs associated with licensing and promotion agreements. c. As of September 30, 2022, the Company had various guarantees and letters of credit totaling $ 5.0 . d. In connection with the Flawless Acquisition, the Company was obligated to pay an additional amount of up to $ 425.0 based on sales performance through 2021 . The initial fair value of this business acquisition liability, established in the purchase price allocation, was $ 182.0 . During the years ended December 31, 2021 and 2020, the Company decreased the fair value of the business acquisition liability by $ 98.0 and by $ 94.0 , respectively, based on updated sales forecasts. As a result of these adjustments, the fair value of this business acquisition liability was $ 0.0 as of December 31, 2021, which was the end of the earn-out period. The changes in fair value were recorded in SG&A within the Consumer Domestic and Consumer International segment s . In connection with the Zicam Acquisition, which was acquired on December 1, 2020, the Company deferred an additional cash payment of $ 20.0 related to certain indemnifications provided by the seller. Any amount that may be due is payable five years from the closing. In connection with the TheraBreath Acquisition, which was acquired on December 21, 2021, the Company deferred an additional cash payment of $ 14.0 related to certain indemnity obligations provided by the seller. The additional amount, to the extent not used in satisfaction of such indemnity obligations, is payable in installments between two and four years from the closin g. Legal proceedings e. In conjunction with the Company’s acquisition and divestiture activities, the Company entered into select guarantees and indemnifications of performance with respect to the fulfillment of the Company’s commitments under applicable purchase and sale agreements. The arrangements generally indemnify the buyer or seller for damages associated with breach of contract, inaccuracies in representations and warranties surviving the closing date and satisfaction of liabilities and commitments retained under the applicable contract. Representations and warranties that survive the closing date generally survive for periods up to five years or the expiration of the applicable statutes of limitations. Potential losses under the indemnifications are generally limited to a portion of the original transaction price, or to other lesser specific dollar amounts for select provisions. With respect to sale transactions, the Company also routinely enters into non-competition agreements for varying periods of time. Guarantees and indemnifications with respect to acquisition and divestiture activities, if triggered, could have a materially adverse impact on the Company’s financial condition, results of operations and cash flows. f. In addition to the matters described above, from time to time in the ordinary course of its business the Company is the subject of, or party to, various pending or threatened legal, regulatory or governmental actions or other proceedings, including, without limitation, those relating to, intellectual property, commercial transactions, product liability, purported consumer class actions, employment matters, antitrust, environmental, health, safety and other compliance related matters. Such proceedings are generally subject to considerable uncertainty and their outcomes, and any related damages, may not be reasonably predictable or estimable. Any such proceedings could result in a material adverse outcome negatively impacting the Company’s business, financial condition, results of operations or cash flows.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	17. Related Party Transactions The following summarizes the balances and transactions between the Company and Armand Products Company (“Armand”) and The ArmaKleen Company (“ArmaKleen”), in each of which the Company holds a 50 % ownership interest: Armand ArmaKleen Nine Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Purchases by Company $ 10.9 $ 9.8 $ 0.0 $ 0.0 Sales by Company $ 0.0 $ 0.0 $ 0.6 $ 0.8 Outstanding Accounts Receivable $ 0.5 $ 0.4 $ 0.9 $ 0.5 Outstanding Accounts Payable $ 1.6 $ 1.4 $ 0.0 $ 0.0 Administration & Management Oversight Services (1) $ 1.7 $ 1.6 $ 1.5 $ 1.5 (1) Billed by the Company and recorded as a reduction of SG&A expenses .

Segments

Segments	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Segments	18. Segments Segment Information The Company operates three reportable segments: Consumer Domestic, Consumer International and Specialty Products Division. These segments are determined based on differences in the nature of products and organizational structure. The Company also has a Corporate segment. Segment revenues are derived from the sale of the following products: Segment Products Consumer Domestic Household and personal care products Consumer International Primarily personal care products SPD Specialty chemical products The Corporate segment income consists of equity in earnings of affiliates. As of September 30, 2022 , the Company held 50 % ownership interests in each of Armand and ArmaKleen, respectively . The Company’s equity in earnings of Armand and ArmaKleen, totaling $ 3.7 and $ 2.0 for the three months ended September 30, 2022 and 2021, respectively, and $ 10.0 and $ 7.4 for the nine months ended September 30, 2022 and 2021, respectively, are included in the Corporate segment. Certain subsidiaries that are included in the Consumer International segment manufacture and sell personal care products to the Consumer Domestic segment. These sales are eliminated from the Consumer International segment results set forth in the table below. Segment net sales and income before income taxes are as follows: Consumer Consumer Domestic International SPD Corporate (3) Total Net Sales (1) Third Quarter 2022 $ 1,010.4 $ 219.7 $ 87.2 $ 0.0 $ 1,317.3 Third Quarter 2021 998.1 227.0 86.3 0.0 1,311.4 First Nine Months of 2022 $ 3,010.2 $ 664.8 $ 264.6 $ 0.0 $ 3,939.6 First Nine Months of 2021 2,900.2 670.2 251.0 0.0 3,821.4 Income before Income Taxes (2) Third Quarter 2022 $ 193.9 $ 22.7 $ 14.2 $ 3.7 $ 234.5 Third Quarter 2021 (4) 238.6 34.5 14.2 2.0 289.3 First Nine Months of 2022 $ 618.3 $ 80.8 $ 38.1 $ 10.0 $ 747.2 First Nine Months of 2021 (4) 713.7 110.9 35.6 7.4 867.6 (1) Intersegment sales from Consumer International to Consumer Domestic, which are not reflected in the table, were $ 3.9 and $ 2.6 for the three months ended September 30, 2022 and September 30, 2021, respectively, and were $ 12.5 and $ 7.8 for the nine months ended September 30, 2022 and September 30, 2021, respectively. (2) In determining income before income taxes, interest expense, investment earnings and certain aspects of other income and expense were allocated among segments based upon each segment’s relative income from operations. (3) The Corporate segment consists of equity in earnings of affiliates from Armand and ArmaKleen for the three and nine months ended September 30, 2022 and September 30, 2021. (4) Results for the three months ended September 30, 2021 include a $ 41.0 reduction of SG&A expenses to adjust the Flawless business acquisition liability, of which $ 34.8 was recorded to Consumer Domestic and $ 6.2 was recorded to Consumer International. Results for the nine months ended September 30, 2021 include a $ 98.0 reduction of SG&A expenses to adjust the Flawless business acquisition liability, of which $ 83.2 was recorded to Consumer Domestic and $ 14.8 was recorded to Consumer International. Product line revenues from external customers are as follows: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Household Products $ 592.3 $ 535.5 $ 1,685.6 $ 1,553.7 Personal Care Products 418.1 462.6 1,324.6 1,346.5 Total Consumer Domestic 1,010.4 998.1 3,010.2 2,900.2 Total Consumer International 219.7 227.0 664.8 670.2 Total SPD 87.2 86.3 264.6 251.0 Total Consolidated Net Sales $ 1,317.3 $ 1,311.4 $ 3,939.6 $ 3,821.4 Household Products include laundry, deodorizing and cleaning products. Personal Care Products include condoms, pregnancy kits, oral care products, skin care and hair care products, cold and remedy products, and gummy dietary supplements.

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Event On August 31, 2022, the Company entered into an Agreement and Plan of Merger pursuant to which the Company agreed to acquire all of the issued and outstanding shares of capital stock of Hero Cosmetics, Inc., the developer of the Hero Mighty Patch® brand and other acne treatment products (the “Hero Acquisition”). The total consideration related to the Hero Acquisition, which is subject to adjustment, consists of a purchase price of approximately $ 565.0 million of cash (of which $ 8.0 million will be held back for five years to satisfy certain indemnification obligations) and approximately $ 65.0 million of restricted shares of the Company's common stock which will be recognized as compensation expense as the stock is subject to vesting requirements for individuals who will continue to be employed by the Company. The Hero Acquisition closed on October 13, 2022 and was financed with cash on hand and commercial paper borrowings. The Company is in the process of completing the initial purchase price allocation for the acquisition which will primarily consist of acquired intangibles. As such, required disclosures will be presented in future periods.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In March 2020, the FASB issued new accounting guidance intended to provide temporary optional expedients and exceptions to the U.S. GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from the London Interbank Offered Rate (“LIBOR”) and other interbank offered rates to alternative reference rates. This guidance was effective beginning on March 12, 2020, and the Company may apply the amendments prospectively to contract modifications made or relationships entered into or evaluated through December 31, 2022. The adoption of this guidance did not have an impact on the Company’s consolidated financial position, results of operations or cash flows in the current period. The Company will continue to evaluate the impacts of this guidance on future contracts through December 31, 2022.
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted In September 2022, the FASB issued new accounting guidance intended to add certain qualitative and quantitative disclosure requirements for a buyer in a supplier finance program. The amendments require a buyer that uses supplier finance programs to make annual disclosures about the program’s key terms, the balance sheet presentation of related amounts, the confirmed amount outstanding at the end of the period, and associated rollforward information. Only the amount outstanding at the end of the period must be disclosed in interim periods. The amendments are effective for all entities for fiscal years beginning after December 15, 2022 on a retrospective basis, including interim periods within those fiscal years, except for the requirement to disclose rollforward information, which is effective prospectively for fiscal years beginning after December 15, 2023. The Company is currently evaluating the impact of adoption, which is expected to result in additional disclosures in 2023.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Components of Inventories	Inventories consist of the following: September 30, December 31, 2022 2021 Raw materials and supplies $ 145.1 $ 116.2 Work in process 51.6 40.0 Finished goods 478.6 379.2 Total $ 675.3 $ 535.4

Property, Plant and Equipment_2

Property, Plant and Equipment, Net ("PP&E") (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Components of Property, Plant and Equipment	PP&E consists of the following: September 30, December 31, 2022 2021 Land $ 28.1 $ 28.3 Buildings and improvements 292.2 290.8 Machinery and equipment 851.9 828.9 Software 110.6 107.8 Office equipment and other assets 93.8 92.7 Construction in progress 175.7 104.3 Gross PP&E 1,552.3 1,452.8 Less accumulated depreciation and amortization 836.0 800.1 Net PP&E $ 716.3 $ 652.7 Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Depreciation expense on PP&E $ 16.7 $ 17.2 $ 50.1 $ 51.3

Earnings Per Share ("EPS") (Tab

Earnings Per Share ("EPS") (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Reconciliation Of Weighted Average Number Of Common Shares Outstanding	The following table sets forth a reconciliation of the weighted average number of shares of Common Stock outstanding to the weighted average number of shares outstanding on a diluted basis: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Weighted average common shares outstanding - basic 242.8 245.3 242.7 245.2 Dilutive effect of stock options 3.2 4.5 3.7 4.7 Weighted average common shares outstanding - diluted 246.0 249.8 246.4 249.9 Antidilutive stock options outstanding 3.0 1.6 3.0 1.6

Stock Based Compensation Plans

Stock Based Compensation Plans (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Option Activity	The following table provides a summary of option activity: Weighted Average Weighted Remaining Average Contractual Aggregate Exercise Term Intrinsic Options Price (in Years) Value Outstanding at December 31, 2021 11.3 $ 58.83 Granted 1.5 85.21 Exercised ( 0.6 ) 40.81 Cancelled ( 0.3 ) 78.76 Outstanding at September 30, 2022 11.9 $ 62.53 5.9 $ 159.0 Exercisable at September 30, 2022 7.3 $ 50.77 4.2 $ 159.0
Information Regarding Intrinsic Value of Stock Options Exercised and Stock Compensation Expense Related to Stock Option Awards	The following table provides information regarding the intrinsic value of stock options exercised and stock compensation expense related to stock option awards: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Intrinsic Value of Stock Options Exercised $ 3.3 $ 12.0 $ 29.6 $ 30.8 Stock Compensation Expense Related to Stock Option Awards $ 4.1 $ 3.4 $ 21.6 $ 19.9 Issued Stock Options 0.0 0.0 1.5 1.5 Weighted Average Fair Value of Stock Options issued (per share) $ 0.0 $ 0.0 $ 21.48 $ 17.33 Fair Value of Stock Options Issued $ 0.0 $ 0.0 $ 32.7 $ 26.1
Assumptions Used in Valuation of Issued Stock Options	The following table provides a summary of the assumptions used in the valuation of issued stock options: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Risk-free interest rate - - 2.9 % 1.3 % Expected life in years - - 7.1 7.2 Expected volatility - - 21.7 % 20.7 % Dividend yield - - 1.2 % 1.2 %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Carrying Amounts and Estimated Fair Values of Other Financial Instruments	The following table provides the carrying amounts and estimated fair values of the Company’s financial instruments at September 30, 2022 and December 31, 2021: September 30, 2022 December 31, 2021 Input Carrying Fair Carrying Fair Level Amount Value Amount Value Financial Assets: Cash equivalents Level 1 $ 192.0 $ 192.0 $ 17.1 $ 17.1 Financial Liabilities: Short-term borrowings Level 2 3.3 3.3 252.8 252.8 2.45 % Senior notes due August 1, 2022 Level 2 0.0 0.0 300.0 302.9 2.875 % Senior notes due October 1, 2022 Level 2 400.0 400.0 399.9 406.4 Term loan due December 22, 2024 Level 2 400.0 400.0 400.0 400.0 3.15 % Senior notes due August 1, 2027 Level 2 424.8 387.7 424.7 450.1 2.3 % Senior notes due December 15, 2031 Level 2 399.2 313.2 399.2 403.5 3.95 % Senior notes due August 1, 2047 Level 2 397.6 313.5 397.5 471.6 5.00 % Senior notes due June 15, 2052 Level 2 499.8 458.3 0.0 0.0 Interest Rate Lock Agreement (asset) liability Level 2 ( 12.5 ) ( 12.5 ) 41.6 41.6 Business Acquisition Liabilities Level 3 34.0 34.0 34.0 34.0

Derivative Instruments and Ri_2

Derivative Instruments and Risk Management (Tables)	9 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Notional Amounts	The notional amount of a derivative instrument is the nominal or face amount used to calculate payments made on that instrument. Notional amounts are presented in the following table: Notional Notional Amount Amount September 30, 2022 December 31, 2021 Derivatives designated as hedging instruments Foreign exchange contracts $ 219.9 $ 216.3 Interest rate lock agreements $ 500.0 $ 300.0 Diesel fuel contracts 3.9 gallons 0.0 gallons Commodities contracts 8.6 pounds 72.1 pounds Derivatives not designated as hedging instruments Foreign exchange contracts $ 5.9 $ 5.9 Equity derivatives $ 23.8 $ 28.9

Acquisition (Tables)

Acquisition (Tables)	9 Months Ended
	Sep. 30, 2022
Zicam Acquisition
Business Acquisition [Line Items]
Fair Values of Assets Acquired	The fair values of the net assets at acquisition are set forth as follows: Inventory and other working capital $ 40.2 Property, plant and equipment 0.5 Trade name 367.8 Other intangible assets 93.8 Goodwill 152.2 Current liabilities ( 13.1 ) Deferred income taxes ( 108.0 ) Long-term liabilities ( 20.7 ) Cash purchase price (net of cash acquired) $ 512.7
Therabreath Acquisition
Business Acquisition [Line Items]
Fair Values of Assets Acquired	The fair values of the net assets at acquisition are set forth as follows: Accounts receivable $ 11.3 Inventory 12.9 Trade name (indefinite lived) 487.0 Other intangible assets 30.1 Goodwill 39.9 Accounts payable and accrued expenses ( 11.2 ) Business acquisition liabilities - long-term ( 14.0 ) Cash purchase price (net of cash acquired) $ 556.0

Goodwill and Other Intangible_2

Goodwill and Other Intangibles, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortizable Intangible Assets	The following table provides information related to the carrying value of all intangible assets, other than goodwill: September 30, 2022 December 31, 2021 Gross Gross Carrying Accumulated Carrying Accumulated Amount Amortization Net Amount Amortization Net Amortizable intangible assets: Trade Names $ 1,384.7 $ ( 384.5 ) $ 1,000.2 $ 1,386.7 $ ( 336.2 ) $ 1,050.5 Customer Relationships 664.0 ( 349.3 ) 314.7 664.0 ( 322.4 ) 341.6 Patents/Formulas 239.1 ( 110.6 ) 128.5 239.1 ( 99.4 ) 139.7 Total $ 2,287.8 $ ( 844.4 ) $ 1,443.4 $ 2,289.8 $ ( 758.0 ) $ 1,531.8
Indefinite Lived Intangible Assets	Indefinite Lived Intangible Assets - Gross Carrying Amount September 30, December 31, 2022 2021 Trade Names $ 1,960.7 $ 1,962.5
Carrying Amount of Goodwill	The carrying amount of goodwill is as follows: Consumer Consumer Specialty Domestic International Products Total Balance at December 31, 2021 $ 1,899.8 $ 238.7 $ 136.0 $ 2,274.5 TheraBreath adjustment 0.5 ( 4.3 ) 0.0 ( 3.8 ) Balance at September 30, 2022 $ 1,900.3 $ 234.4 $ 136.0 $ 2,270.7

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Summary of Lease Information	A summary of the Company’s lease information is as follows: September 30, December 31, Classification 2022 2021 Assets Right of use assets Other Assets $ 166.7 $ 159.4 Liabilities Current lease liabilities Accounts Payable and Accrued Expenses $ 22.8 $ 24.4 Long-term lease liabilities Deferred and Other Long-term Liabilities 155.5 146.6 Total lease liabilities $ 178.3 $ 171.0 Other information Weighted-average remaining lease term (years) 9.1 9.1 Weighted-average discount rate 4.4 % 4.3 % Three Months Three Months Nine Months Nine Months Ended Ended Ended Ended September 30, 2022 September 30, 2021 September 30, 2022 September 30, 2021 Statement of Income Lease cost (1) $ 7.7 $ 8.1 $ 23.1 $ 24.6 Other information Leased assets obtained in exchange for new lease liabilities net of modifications (2) $ 9.5 $ 0.4 $ 26.8 $ 4.5 Cash paid for amounts included in the measurement of lease liabilities $ 7.8 $ 8.0 $ 23.3 $ 24.5 (1) Lease expense is included in cost of sales or SG&A expenses based on the nature of the leased item. Short-term lease expense is excluded from this amount and is not material. The Company also has certain variable leases which are not material. The non-cash component of lease expense for the first nine months of 2022 and 2021 was $ 18.0 and $ 19.1 , respectively, and is included in the Amortization caption in the condensed consolidated statement of cash flows. In September 2022, the Company amended its contract at one of its international locations. This resulted in an increase to the Company’s right of use assets and corresponding lease liabilities of approximately $ 8.2 recorded in the third quarter of 2022. In June 2022, the Company amended its contract at one of its leased manufacturing facilities. This resulted in an increase to the Company’s right of use assets and corresponding lease liabilities of approximately $ 15.2 recorded in the second quarter of 2022.
Summary of Minimum Annual Rentals Including Reasonably Assured Renewal Options under Lease Agreements	The Company’s minimum annual rentals including reasonably assured renewal options under lease agreements are as follows: Operating Leases 2022 $ 8.1 2023 28.6 2024 27.2 2025 26.1 2026 18.7 2027 and thereafter 112.1 Total future minimum lease commitments 220.8 Less: Imputed interest ( 42.5 ) Present value of lease liabilities $ 178.3

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2022
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consist of the following: September 30, December 31, 2022 2021 Trade accounts payable $ 655.6 $ 663.8 Accrued marketing and promotion costs 196.3 201.6 Accrued wages and related benefit costs 52.5 87.7 Other accrued current liabilities 127.6 166.6 Total $ 1,032.0 $ 1,119.7

Short-Term Borrowings and Lon_2

Short-Term Borrowings and Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Components of Short-Term Borrowings and Long-Term Debt	Short-term borrowings and long-term debt consist of the following: September 30, December 31, 2022 2021 Short-term borrowings Commercial paper issuances $ 0.0 $ 249.7 Various debt due to international banks 3.3 3.1 Total short-term borrowings $ 3.3 $ 252.8 Long-term debt 2.45 % Senior notes due August 1, 2022 0.0 300.0 2.875 % Senior notes due October 1, 2022 (1) 400.0 400.0 Less: Discount 0.0 ( 0.1 ) Term loan due December 22, 2024 400.0 400.0 3.15 % Senior notes due August 1, 2027 425.0 425.0 Less: Discount ( 0.2 ) ( 0.3 ) 2.3 % Senior notes due December 15, 2031 400.0 400.0 Less: Discount ( 0.8 ) ( 0.8 ) 3.95 % Senior notes due August 1, 2047 400.0 400.0 Less: Discount ( 2.4 ) ( 2.5 ) 5.00 % Senior notes due June 15, 2052 500.0 0.0 Less: Discount ( 0.2 ) 0.0 Debt issuance costs, net ( 17.0 ) ( 11.2 ) Total long-term debt 2,504.4 2,310.1 Less: Current maturities ( 400.0 ) ( 699.4 ) Net long-term debt $ 2,104.4 $ 1,610.7 (1) In October 2022, the Company repaid the full amount of the 2.875 % Senior Notes due October 1, 2022 with a portion of the proceeds from the 5.00 % Senior notes issued on June 2, 2022 and due June 15, 2052 and cash on hand.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Components of Changes in Accumulated Other Comprehensive Income (Loss)	The components of changes in accumulated other comprehensive income (loss) are as follows: Accumulated Foreign Defined Other Currency Benefit Derivative Comprehensive Adjustments Plans Agreements Income (Loss) Balance at December 31, 2020 $ ( 26.4 ) $ 0.0 $ ( 51.2 ) $ ( 77.6 ) Other comprehensive income (loss) before reclassifications ( 4.7 ) ( 0.9 ) 32.4 26.8 Amounts reclassified to consolidated statement of (a) (b) 0.0 0.0 ( 2.9 ) ( 2.9 ) Tax benefit (expense) 0.0 0.2 ( 7.4 ) ( 7.2 ) Other comprehensive income (loss) ( 4.7 ) ( 0.7 ) 22.1 16.7 Balance at September 30, 2021 $ ( 31.1 ) $ ( 0.7 ) $ ( 29.1 ) $ ( 60.9 ) Balance at December 31, 2021 $ ( 30.2 ) $ ( 0.6 ) $ ( 37.4 ) $ ( 68.2 ) Other comprehensive income (loss) before reclassifications ( 27.8 ) 2.5 66.1 40.8 Amounts reclassified to consolidated statement of (a) (b) 0.0 0.0 ( 1.2 ) ( 1.2 ) Tax benefit (expense) 0.0 ( 0.6 ) ( 16.9 ) ( 17.5 ) Other comprehensive income (loss) ( 27.8 ) 1.9 48.0 22.1 Balance at September 30, 2022 $ ( 58.0 ) $ 1.3 $ 10.6 $ ( 46.1 ) (a) Amounts reclassified to cost of sales, selling, general and administrative expenses or interest expense. The Company reclassified a gain of $ 0.9 and a gain of $ 2.5 to the condensed consolidated statements of income during the three months ended September 30, 2022 and 2021, respectively.

Related Party Transactions (Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	The following summarizes the balances and transactions between the Company and Armand Products Company (“Armand”) and The ArmaKleen Company (“ArmaKleen”), in each of which the Company holds a 50 % ownership interest: Armand ArmaKleen Nine Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Purchases by Company $ 10.9 $ 9.8 $ 0.0 $ 0.0 Sales by Company $ 0.0 $ 0.0 $ 0.6 $ 0.8 Outstanding Accounts Receivable $ 0.5 $ 0.4 $ 0.9 $ 0.5 Outstanding Accounts Payable $ 1.6 $ 1.4 $ 0.0 $ 0.0 Administration & Management Oversight Services (1) $ 1.7 $ 1.6 $ 1.5 $ 1.5

Segments (Tables)

Segments (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Selected Financial Information Relating To Company's Segments	Segment net sales and income before income taxes are as follows: Consumer Consumer Domestic International SPD Corporate (3) Total Net Sales (1) Third Quarter 2022 $ 1,010.4 $ 219.7 $ 87.2 $ 0.0 $ 1,317.3 Third Quarter 2021 998.1 227.0 86.3 0.0 1,311.4 First Nine Months of 2022 $ 3,010.2 $ 664.8 $ 264.6 $ 0.0 $ 3,939.6 First Nine Months of 2021 2,900.2 670.2 251.0 0.0 3,821.4 Income before Income Taxes (2) Third Quarter 2022 $ 193.9 $ 22.7 $ 14.2 $ 3.7 $ 234.5 Third Quarter 2021 (4) 238.6 34.5 14.2 2.0 289.3 First Nine Months of 2022 $ 618.3 $ 80.8 $ 38.1 $ 10.0 $ 747.2 First Nine Months of 2021 (4) 713.7 110.9 35.6 7.4 867.6
Product Line Revenues From External Customers	Product line revenues from external customers are as follows: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2022 2021 2022 2021 Household Products $ 592.3 $ 535.5 $ 1,685.6 $ 1,553.7 Personal Care Products 418.1 462.6 1,324.6 1,346.5 Total Consumer Domestic 1,010.4 998.1 3,010.2 2,900.2 Total Consumer International 219.7 227.0 664.8 670.2 Total SPD 87.2 86.3 264.6 251.0 Total Consolidated Net Sales $ 1,317.3 $ 1,311.4 $ 3,939.6 $ 3,821.4

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Research and development expenses	$ 29.2	$ 27.7	$ 80.9	$ 77.2

Components of Inventories (Deta

Components of Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Inventory, Finished Goods and Work in Process, Net of Reserves [Abstract]
Raw materials and supplies	$ 145.1	$ 116.2
Work in process	51.6	40
Finished goods	478.6	379.2
Total	$ 675.3	$ 535.4

Components of Property, Plant a

Components of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Gross PP&E	$ 1,552.3	$ 1,452.8
Less accumulated depreciation and amortization	836	800.1
Net PP&E	716.3	652.7
Land
Property, Plant and Equipment [Line Items]
Gross PP&E	28.1	28.3
Building and Building Improvements
Property, Plant and Equipment [Line Items]
Gross PP&E	292.2	290.8
Machinery and Equipment
Property, Plant and Equipment [Line Items]
Gross PP&E	851.9	828.9
Software
Property, Plant and Equipment [Line Items]
Gross PP&E	110.6	107.8
Office equipment and other assets
Property, Plant and Equipment [Line Items]
Gross PP&E	93.8	92.7
Construction in progress
Property, Plant and Equipment [Line Items]
Gross PP&E	$ 175.7	$ 104.3

Depreciation and Interest Charg

Depreciation and Interest Charges on Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense on PP&E	$ 16.7	$ 17.2	$ 50.1	$ 51.3

Reconciliation of Weighted Aver

Reconciliation of Weighted Average Number of Shares of Common Stock Outstanding (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Weighted average shares outstanding - Basic	242.8	245.3	242.7	245.2
Dilutive effect of stock options	3.2	4.5	3.7	4.7
Weighted average common shares outstanding - diluted	246	249.8	246.4	249.9
Antidilutive stock options outstanding	3	1.6	3	1.6

Summary of Option Activity (Det

Summary of Option Activity (Details) $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Beginning Balance, Options | shares	11.3
Granted, Options | shares	1.5
Exercised, Options | shares	(0.6)
Cancelled, Options | shares	(0.3)
Ending Balance, Options | shares	11.9
Exercisable September 30, 2022 | shares	7.3
Beginning Balance, Weighted-Average Exercise Price | $ / shares	$ 58.83
Granted, Weighted-Average Exercise Price | $ / shares	85.21
Exercised, Weighted-Average Exercise Price | $ / shares	40.81
Cancelled, Weighted-Average Exercise Price | $ / shares	78.76
Ending Balance, Weighted-Average Exercise Price | $ / shares	62.53
Exercisable at September 30, 2022 Weighted-Average Exercise Price | $ / shares	$ 50.77
Outstanding at September 30, 2022, Weighted-Average Remaining Contractual Term, years	5 years 10 months 24 days
Exercisable at September 30, 2022, Weighted-Average Remaining Contractual Term, years	4 years 2 months 12 days
Outstanding at September 30, 2022, Aggregate Intrinsic Value | $	$ 159
Exercisable at September 30, 2022, Aggregate Intrinsic Value | $	$ 159

Schedule of Share Based Compens

Schedule of Share Based Compensation Stock Options (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Intrinsic Value of Stock Options Exercised	$ 3.3	$ 12	$ 29.6	$ 30.8
Stock Compensation Expense Related to Stock Option Awards	$ 4.1	$ 3.4	$ 21.6	$ 19.9
Issued Stock Options	0	0	1.5	1.5
Weighted Average Fair Value of Stock Options issued (per share)	$ 0	$ 0	$ 21.48	$ 17.33
Fair Value of Stock Options Issued	$ 0	$ 0	$ 32.7	$ 26.1

Assumptions Used in Valuation o

Assumptions Used in Valuation of Issued Stock Options (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	0%	0%	2.90%	1.30%
Expected life in years			7 years 1 month 6 days	7 years 2 months 12 days
Expected volatility	0%	0%	21.70%	20.70%
Dividend yield	0%	0%	1.20%	1.20%

Share Repurchases - Additional

Share Repurchases - Additional Information (Details) - USD ($) $ in Millions	1 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2021	Feb. 28, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Oct. 28, 2021
Accelerated Share Repurchases [Line Items]
Stock repurchase program, authorized amount						$ 1,000
Payment for share repurchase			$ 0	$ 54.9
Commercial Bank
Accelerated Share Repurchases [Line Items]
Stock repurchase program, authorized amount	$ 180				$ 180
Accelerated share repurchases, settlement payment	$ 200				$ 200
Accelerated share repurchases received	1,800,000	200,000
Evergreen Program
Accelerated Share Repurchases [Line Items]
Payment for share repurchase	$ 100
Share Repurchase Program
Accelerated Share Repurchases [Line Items]
Open market share repurchase	1,800,000
Open market share repurchase amount	$ 170.3
Accelerated share repurchases received					2,000,000
Stock repurchased during period, shares			729,700,000
Payment for share repurchase	$ 70.3

Carrying Amounts and Estimated

Carrying Amounts and Estimated Fair Values of Other Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Short-term borrowings	$ 3.3	$ 252.8
Senior Notes	2,504.4	2,310.1
Carrying Amount
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash equivalents	192	17.1
Short-term borrowings	3.3	252.8
Business Acquisition Liabilities	34	34
Fair Value | Fair Value, Inputs, Level 1
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cash equivalents	192	17.1
Fair Value | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Short-term borrowings	3.3	252.8
Fair Value | Fair Value, Inputs, Level 3
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Business Acquisition Liabilities	34	34
Interest Rate Swap | Carrying Amount
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest Rate Lock Agreement (asset) liability	(12.5)	(41.6)
Interest Rate Swap | Fair Value | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest Rate Lock Agreement (asset) liability	(12.5)	(41.6)
2.45% Senior notes due August 1, 2022 | Carrying Amount
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	0	300
2.45% Senior notes due August 1, 2022 | Fair Value | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior notes	0	302.9
2.875% Senior notes due October 1, 2022 | Carrying Amount
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	400	399.9
2.875% Senior notes due October 1, 2022 | Fair Value | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior notes	400	406.4
Term Loan Due December 22, 2024
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Term loan	400	400
Term Loan Due December 22, 2024 | Carrying Amount
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Term loan		400
Senior Notes	400
Term Loan Due December 22, 2024 | Fair Value | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior notes	400	400
3.15% Senior notes due August 1, 2027 | Carrying Amount
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	424.8	424.7
3.15% Senior notes due August 1, 2027 | Fair Value | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior notes	387.7	450.1
2.3% Senior notes due December 15, 2031 | Carrying Amount
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	399.2	399.2
2.3% Senior notes due December 15, 2031 | Fair Value | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior notes	313.2	403.5
3.95% Senior notes due August 1, 2047 | Carrying Amount
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	397.6	397.5
3.95% Senior notes due August 1, 2047 | Fair Value | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior notes	313.5	471.6
5.00% Senior notes due June 15, 2052 [Member] | Carrying Amount
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior Notes	499.8	0
5.00% Senior notes due June 15, 2052 [Member] | Fair Value | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Senior notes	$ 458.3	$ 0

Carrying Amounts and Estimate_2

Carrying Amounts and Estimated Fair Values of Other Financial Instruments (Parenthetical) (Details)	Oct. 31, 2022	Oct. 01, 2022	Sep. 30, 2022	Aug. 01, 2022	Dec. 31, 2021
2.45% Senior notes due August 1, 2022
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate of debt			2.45%	2.45%	2.45%
2.45% Senior notes due August 1, 2022 | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate of debt			2.45%		2.45%
2.875% Senior notes due October 1, 2022
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate of debt	2.875%	2.875%	2.875%		2.875%
2.875% Senior notes due October 1, 2022 | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate of debt			2.875%		2.875%
3.15% Senior notes due August 1, 2027
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate of debt			3.15%		3.15%
3.15% Senior notes due August 1, 2027 | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate of debt			3.15%		3.15%
2.3% Senior notes due December 15, 2031
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate of debt			2.30%		2.30%
2.3% Senior notes due December 15, 2031 | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate of debt			2.30%		2.30%
3.95% Senior notes due August 1, 2047
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate of debt			3.95%		3.95%
3.95% Senior notes due August 1, 2047 | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate of debt			3.95%		3.95%
5.00% Senior notes due June 15, 2052 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate of debt			5%		5%
5.00% Senior notes due June 15, 2052 [Member] | Fair Value, Inputs, Level 2
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate of debt			5%		5%

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	May 01, 2019
Interest Rate Swap Lock Agreement [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Loss on Settlement of Agreements	$ 4.2
Years Amortized Into Interest Expense	10 years
Flawless Acquisition
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Business Acquisition Liabilities		$ 0		$ 182
Flawless Acquisition | Updated Sales Forecasts
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Increase (decrease) in estimate of contingent consideration liability		(98)	$ (94)
Thera Breath Acquisition
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Business Acquisition Liabilities	$ 14	14
Thera Breath Acquisition | Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Business Acquisition Payable Period	4 years
Thera Breath Acquisition | Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Business Acquisition Payable Period	2 years
Zicam Acquisition
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Business Acquisition Liabilities	$ 20	$ 20
Business Acquisition Payable Period	5 years

Schedule of Notional Amounts (D

Schedule of Notional Amounts (Details) lb in Millions, gal in Millions, $ in Millions	Sep. 30, 2022 USD ($) lb gal	Dec. 31, 2021 USD ($) gal lb
Designated as Hedging Instrument | Foreign Exchange Contract
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivatives, Notional Amount	$ 219.9	$ 216.3
Designated as Hedging Instrument | Interest rate lock agreements
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivatives, Notional Amount	$ 500	$ 300
Designated as Hedging Instrument | Diesel fuel contracts
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivatives, Notional Amount, Volume | gal	3.9	0
Designated as Hedging Instrument | Commodities Contracts
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivatives, Notional Amount, Volume | lb	8.6	72.1
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivatives, Notional Amount	$ 5.9	$ 5.9
Not Designated as Hedging Instrument | Equity derivatives
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivatives, Notional Amount	$ 23.8	$ 28.9

Derivative Instruments and Ri_3

Derivative Instruments and Risk Management (Additional Information) (Details) - Interest Rate Swap Lock Agreement [Member] $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Loss on Settlement of Agreements	$ 4.2
Amortized into Interest Expense	10 years

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) - USD ($) $ in Millions

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Dec. 24, 2021

Dec. 24, 2021

Dec. 01, 2020

May 01, 2019

Dec. 31, 2020

Sep. 30, 2022

Sep. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Dec. 31, 2021

Dec. 31, 2020

Dec. 10, 2021

Business Acquisition [Line Items]

Net Sales

$ 1,317.3

$ 1,311.4

$ 3,939.6

$ 3,821.4

Maximum

Business Acquisition [Line Items]

Average life of the intangible assets, years

20 years

Thera Breath Acquisition

Business Acquisition [Line Items]

Closing payment of net of cash acquired

$ 556

$ 556

Additional cash payment

14

14

Net Sales

$ 100

Proceeds from term loan for business acquisition

$ 400

Financing term loan period

3 years

Underwritten public offering senior notes

$ 400

Business Acquisition Liabilities

14

$ 14

14

Thera Breath Acquisition | Maximum

Business Acquisition [Line Items]

Business acquisition, period

4 years

4 years

Average life of the intangible assets, years

20 years

Thera Breath Acquisition | Minimum

Business Acquisition [Line Items]

Business acquisition, period

2 years

2 years

Average life of the intangible assets, years

10 years

Zicam Acquisition

Business Acquisition [Line Items]

Closing payment of net of cash acquired

$ 512.7

$ 512.7

$ 512.7

Additional cash payment

$ 20

$ 20

Business acquisition, period

5 years

5 years

Net Sales

$ 107

Business Acquisition Liabilities

$ 20

$ 20

$ 20

Zicam Acquisition | Maximum

Business Acquisition [Line Items]

Average life of the intangible assets, years

20 years

20 years

Zicam Acquisition | Minimum

Business Acquisition [Line Items]

Average life of the intangible assets, years

10 years

Fair Values of Net Assets Acqui

Fair Values of Net Assets Acquired (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 01, 2020
Business Acquisition [Line Items]
Goodwill	$ 2,270.7	$ 2,274.5
Zicam Acquisition
Business Acquisition [Line Items]
Inventory and other working capital				$ 40.2
Property, plant and equipment				0.5
Trade name				367.8
Other intangible assets				93.8
Goodwill		$ 2,274.5		152.2
Current liabilities				(13.1)
Deferred income taxes				(108)
Long-term liabilities				(20.7)
Cash purchase price (net of cash acquired)			$ 512.7	$ 512.7
THERABREATH
Business Acquisition [Line Items]
Accounts receivable	11.3
Inventory	12.9
Trade name	487
Other intangible assets	30.1
Goodwill	39.9
Accounts payable and accrued expenses	(11.2)
Long-term liabilities	(14)
Cash purchase price (net of cash acquired)	$ 556

Amortizable Intangible Assets (

Amortizable Intangible Assets (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,287.8	$ 2,289.8
Accumulated Amortization	(844.4)	(758)
Net	1,443.4	1,531.8
Trade Names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,384.7	1,386.7
Accumulated Amortization	(384.5)	(336.2)
Net	1,000.2	1,050.5
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	664	664
Accumulated Amortization	(349.3)	(322.4)
Net	314.7	341.6
Patents/Formulas
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	239.1	239.1
Accumulated Amortization	(110.6)	(99.4)
Net	$ 128.5	$ 139.7

Indefinite Lived Intangible Ass

Indefinite Lived Intangible Assets (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Trade Names
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Trade names	$ 1,960.7	$ 1,962.5

Goodwill and Other Intangible_3

Goodwill and Other Intangibles, Net - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Amortization expense of intangible assets	$ 29.3	$ 29.9	$ 88.1	$ 90.9
Estimated amortization expense, 2022	117		117
Gross Carrying Amount	2,287.8		2,287.8		$ 2,289.8
Percent of fair value in excess of carrying value					70%
Average royalty rate					10%
Net book value	1,443.4		1,443.4		$ 1,531.8
U.S
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Fair value assumptions discount rate					7%
International
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Fair value assumptions discount rate					8.50%
Trojan Trade Name
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Gross Carrying Amount					$ 176.4
Trade Name and Other Intangible Assets
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Carrying value of assets	11.3		11.3
Net book value	8.5		$ 8.5
Remaining amortization period			6 years
Flawless Trade Name
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Carrying value of assets	465		$ 465
Remaining amortization period			16 years
Percentage Of Cash Flows Exceeding Carrying Value Of The Long Lived Assets			10%
Maximum
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Estimated amortization expense, 2023	115		$ 115
Estimated amortization expense, 2024	115		115
Estimated amortization expense, 2025	115		115
Estimated amortization expense, 2026	115		115
Minimum
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Estimated amortization expense, 2023	107		107
Estimated amortization expense, 2024	107		107
Estimated amortization expense, 2025	107		107
Estimated amortization expense, 2026	107		107
Estimated amortization expense, 2027	$ 107		$ 107

Carrying Amount of Goodwill (De

Carrying Amount of Goodwill (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Goodwill [Line Items]
Beginning balance	$ 2,274.5
Ending balance	2,270.7
Zicam Acquisition
Goodwill [Line Items]
Beginning balance	2,274.5
Thera Breath Acquisition
Goodwill [Line Items]
TheraBreath adjustment	(3.8)
Consumer Domestic | Zicam Acquisition
Goodwill [Line Items]
Beginning balance	1,899.8
Ending balance	1,900.3
Consumer Domestic | Thera Breath Acquisition
Goodwill [Line Items]
TheraBreath adjustment	0.5
Consumer International | Zicam Acquisition
Goodwill [Line Items]
Beginning balance	238.7
Ending balance	234.4
Consumer International | Thera Breath Acquisition
Goodwill [Line Items]
TheraBreath adjustment	(4.3)
Specialty Products | Zicam Acquisition
Goodwill [Line Items]
Beginning balance	136
Ending balance	136
Specialty Products | Thera Breath Acquisition
Goodwill [Line Items]
TheraBreath adjustment	$ 0

Summary of Lease information (D

Summary of Lease information (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Leases [Abstract]
Right of use assets		$ 166.7		$ 166.7		$ 159.4
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]		Other Assets, Noncurrent		Other Assets, Noncurrent		Other Assets, Noncurrent
Current lease liabilities		$ 22.8		$ 22.8		$ 24.4
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]		Accounts Payable and Accrued Liabilities, Current		Accounts Payable and Accrued Liabilities, Current		Accounts Payable and Accrued Liabilities, Current
Long-term lease liabilities		$ 155.5		$ 155.5		$ 146.6
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]		Other Liabilities, Noncurrent		Other Liabilities, Noncurrent		Other Liabilities, Noncurrent
Total lease liabilities		$ 178.3		$ 178.3		$ 171
Weighted-average remaining lease term (years)		9 years 1 month 6 days		9 years 1 month 6 days		9 years 1 month 6 days
Weighted-average discount rate		4.40%		4.40%		4.30%
Lease cost	[1]	$ 7.7	$ 8.1	$ 23.1	$ 24.6
Leased assets obtained in exchange for new lease liabilities net of modifications	[2]	9.5	0.4	26.8	4.5
Cash paid for amounts included in the measurement of lease liabilities		$ 7.8	$ 8	$ 23.3	$ 24.5
[1] Lease expense is included in cost of sales or SG&A expenses based on the nature of the leased item. Short-term lease expense is excluded from this amount and is not material. The Company also has certain variable leases which are not material. The non-cash component of lease expense for the first nine months of 2022 and 2021 was $ 18.0 and $ 19.1 , respectively, and is included in the Amortization caption in the condensed consolidated statement of cash flows. In September 2022, the Company amended its contract at one of its international locations. This resulted in an increase to the Company’s right of use assets and corresponding lease liabilities of approximately $ 8.2 recorded in the third quarter of 2022. In June 2022, the Company amended its contract at one of its leased manufacturing facilities. This resulted in an increase to the Company’s right of use assets and corresponding lease liabilities of approximately $ 15.2 recorded in the second quarter of 2022.

Summary of Lease information (P

Summary of Lease information (Parenthetical) (Details) - USD ($) $ in Millions	6 Months Ended	9 Months Ended
	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Leases [Abstract]
Non-cash component of lease expense		$ 18	$ 19.1
Increase (decrease) in right-of-use asset	$ 15.2	8.2
Increase (decrease) in operating lease liabilities	$ 15.2	$ 8.2

Summary of Minimum Annual Renta

Summary of Minimum Annual Rentals Including Reasonably Assured Renewal Options under Lease Agreements (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Operating Leases
2022	$ 8.1
2023	28.6
2024	27.2
2025	26.1
2026	18.7
2027 and thereafter	112.1
Total future minimum lease commitments	220.8
Less: Imputed interest	(42.5)
Present value of lease liabilities	$ 178.3	$ 171

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Accounts Payable and Accrued Liabilities, Current [Abstract]
Trade accounts payable	$ 655.6	$ 663.8
Accrued marketing and promotion costs	196.3	201.6
Accrued wages and related benefit costs	52.5	87.7
Other accrued current liabilities	127.6	166.6
Total	$ 1,032	$ 1,119.7

Summary of Short-Term Borrowing

Summary of Short-Term Borrowings and Long-Term Debt (Details) - USD ($) $ in Millions	Oct. 01, 2022	Sep. 30, 2022		Aug. 01, 2022	Dec. 31, 2021
Short-term borrowings
Commercial paper issuances		$ 0			$ 249.7
Various debt due to international banks		3.3			3.1
Total short-term borrowings		3.3			252.8
Long-term debt
Debt issuance costs, net		(17)			(11.2)
Long-term Debt, Total		2,504.4			2,310.1
Less: Current maturities		(400)			(699.4)
Net long-term debt		2,104.4			1,610.7
2.45% Senior notes due August 1, 2022
Long-term debt
Senior notes		0		$ 300	300
2.875% Senior notes due October 1, 2022
Long-term debt
Senior notes	$ 400	400	[1]		400	[1]
Less: Discount		0			(0.1)
Term Loan Due December 22, 2024
Long-term debt
Term loan		400			400
3.15% Senior notes due August 1, 2027
Long-term debt
Senior notes		425			425
Less: Discount		(0.2)			(0.3)
2.3% Senior notes due December 15, 2031
Long-term debt
Senior notes		400			400
Less: Discount		(0.8)			(0.8)
3.95% Senior notes due August 1, 2047
Long-term debt
Senior notes		400			400
Less: Discount		(2.4)			(2.5)
5.00% Senior notes due June 15, 2052
Long-term debt
Senior notes		500			0
Less: Discount		(0.2)			$ 0
Term loan		$ 500
[1] In October 2022, the Company repaid the full amount of the 2.875 % Senior Notes due October 1, 2022 with a portion of the proceeds from the 5.00 % Senior notes issued on June 2, 2022 and due June 15, 2052 and cash on hand.

Summary of Short-Term Borrowi_2

Summary of Short-Term Borrowings and Long-Term Debt (Parenthetical) (Details)		9 Months Ended	12 Months Ended
	Oct. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Oct. 01, 2022	Aug. 01, 2022
2.45% Senior notes due August 1, 2022
Debt Instrument [Line Items]
Interest rate of debt		2.45%	2.45%		2.45%
Maturity date of debt		Aug. 01, 2022	Aug. 01, 2022
2.875% Senior notes due October 1, 2022
Debt Instrument [Line Items]
Interest rate of debt	2.875%	2.875%	2.875%	2.875%
Maturity date of debt	Oct. 01, 2022	Oct. 01, 2022	Oct. 01, 2022
3.15% Senior notes due August 1, 2027
Debt Instrument [Line Items]
Interest rate of debt		3.15%	3.15%
Maturity date of debt		Aug. 01, 2027	Aug. 01, 2027
2.3% Senior notes due December 15, 2031
Debt Instrument [Line Items]
Interest rate of debt		2.30%	2.30%
Maturity date of debt		Dec. 15, 2031	Dec. 15, 2031
3.95% Senior notes due August 1, 2047
Debt Instrument [Line Items]
Interest rate of debt		3.95%	3.95%
Maturity date of debt		Aug. 01, 2047	Aug. 01, 2047
5.00% Senior notes due June 15, 2052
Debt Instrument [Line Items]
Interest rate of debt	5%	5%	5%
Maturity date of debt	Jun. 15, 2052	Jun. 15, 2052	Jun. 15, 2052

Short-Term Borrowings and Lon_3

Short-Term Borrowings and Long-Term Debt (Additional Information) (Details) - USD ($) $ in Millions	Mar. 29, 2024	Oct. 31, 2022	Oct. 01, 2022	Sep. 30, 2022		Aug. 01, 2022	Jun. 16, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 1,000
Commercial Paper				0				$ 249.7
Long-Term Debt, Current Maturities				400				699.4
Other Commitment, Total				750
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity							$ 1,500
Long-Term Debt, Current Maturities	$ 1,000,000
5.00% Senior notes due June 15, 2052
Debt Instrument [Line Items]
Senior Notes				$ 500				$ 0
Debt Instrument, Interest Rate, Stated Percentage		5%		5%				5%
Debt Instrument, Face Amount				$ 500
2.45% Senior notes due August 1, 2022
Debt Instrument [Line Items]
Senior Notes				$ 0		$ 300		$ 300
Debt Instrument, Interest Rate, Stated Percentage				2.45%		2.45%		2.45%
2.875% Senior notes due October 1, 2022
Debt Instrument [Line Items]
Senior Notes			$ 400	$ 400	[1]			$ 400	[1]
Debt Instrument, Interest Rate, Stated Percentage		2.875%	2.875%	2.875%				2.875%
[1] In October 2022, the Company repaid the full amount of the 2.875 % Senior Notes due October 1, 2022 with a portion of the proceeds from the 5.00 % Senior notes issued on June 2, 2022 and due June 15, 2052 and cash on hand.

Components of Changes in Accumu

Components of Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance		$ (68.2)	$ (77.6)
Other comprehensive income (loss) before reclassifications		40.8	26.8
Amounts reclassified to consolidated statement of income	[1],[2]	(1.2)	(2.9)
Tax benefit (expense)		(17.5)	(7.2)
Other comprehensive income (loss)		22.1	16.7
Ending balance		(46.1)	(60.9)
Foreign Currency Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance		(30.2)	(26.4)
Other comprehensive income (loss) before reclassifications		(27.8)	(4.7)
Amounts reclassified to consolidated statement of income	[1],[2]	0	0
Tax benefit (expense)		0	0
Other comprehensive income (loss)		(27.8)	(4.7)
Ending balance		(58)	(31.1)
Defined Benefit Plans
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance		(0.6)	0
Other comprehensive income (loss) before reclassifications		2.5	(0.9)
Amounts reclassified to consolidated statement of income	[1],[2]	0	0
Tax benefit (expense)		(0.6)	(0.2)
Other comprehensive income (loss)		1.9	(0.7)
Ending balance		1.3	(0.7)
Derivative Agreements
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance		(37.4)	(51.2)
Other comprehensive income (loss) before reclassifications		66.1	32.4
Amounts reclassified to consolidated statement of income	[1],[2]	(1.2)	(2.9)
Tax benefit (expense)		(16.9)	(7.4)
Other comprehensive income (loss)		48	22.1
Ending balance		$ 10.6	$ (29.1)
[1] Amounts reclassified to cost of sales, selling, general and administrative expenses or interest expense. The Company reclassified a gain of $ 0.9 and a gain of $ 2.5 to the condensed consolidated statements of income during the three months ended September 30, 2022 and 2021, respectively.

Components of Changes in Accu_2

Components of Changes in Accumulated Other Comprehensive Income (Loss) (Parenthetical) (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Statement of Stockholders' Equity [Abstract]
Foreign Currency Gain (Loss) Reclassified to Earnings, Net	$ 0.9	$ 2.5

Commitments, Contingencies an_2

Commitments, Contingencies and Guarantees - Additional Information (Details) $ in Millions		1 Months Ended	9 Months Ended	12 Months Ended
	Dec. 24, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2022 USD ($) Tons	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	May 01, 2019 USD ($)
Commitments And Contingencies Disclosure [Line Items]
Annual purchase commitment, in tons | Tons			240,000
Commitments			$ 314.1
Outstanding guarantees and letters of credit			$ 5
Flawless Acquisition
Commitments And Contingencies Disclosure [Line Items]
Payment year of achieving certain operating performance			2021
Payment to be made if certain operating performance is achieved				$ 0		$ 182
Zicam Acquisition
Commitments And Contingencies Disclosure [Line Items]
Payment to be made if certain operating performance is achieved			$ 20	20
Additional cash payment		$ 20	$ 20
Business acquisition, period		5 years	5 years
Thera Breath Acquisition
Commitments And Contingencies Disclosure [Line Items]
Payment to be made if certain operating performance is achieved			$ 14	14
Additional cash payment	$ 14		$ 14
Minimum | Thera Breath Acquisition
Commitments And Contingencies Disclosure [Line Items]
Business acquisition, period	2 years		2 years
Maximum | Flawless Acquisition
Commitments And Contingencies Disclosure [Line Items]
Additional earn-out payment			$ 425
Maximum | Thera Breath Acquisition
Commitments And Contingencies Disclosure [Line Items]
Business acquisition, period	4 years		4 years
Updated Sales Forecasts | Flawless Acquisition
Commitments And Contingencies Disclosure [Line Items]
Increase (decrease) in estimate of contingent consideration liability				$ (98)	$ (94)

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details)	Sep. 30, 2022	Sep. 30, 2021
Armand Products Company
Schedule of Equity Method Investments [Line Items]
Percentage of ownership interest	50%	50%
ArmaKleen Company
Schedule of Equity Method Investments [Line Items]
Percentage of ownership interest	50%	50%

Balance and Transactions Betwee

Balance and Transactions Between Company and Related Party (Details) - USD ($) $ in Millions		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Armand Products Company
Related Party Transaction [Line Items]
Purchases by Company		$ 10.9	$ 9.8
Sales by Company		0	0
Outstanding Accounts Receivable		0.5	0.4
Outstanding Accounts Payable		1.6	1.4
Administration & Management Oversight Services	[1]	1.7	1.6
ArmaKleen Company
Related Party Transaction [Line Items]
Purchases by Company		0	0
Sales by Company		0.6	0.8
Outstanding Accounts Receivable		0.9	0.5
Outstanding Accounts Payable		0	0
Administration & Management Oversight Services	[1]	$ 1.5	$ 1.5
[1] Billed by the Company and recorded as a reduction of SG&A expenses

Segments - Additional Informati

Segments - Additional Information (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) Segment	Sep. 30, 2021 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | Segment			3
Equity in earnings of affiliates	$ 3.7	$ 2	$ 10	$ 7.4
Armand Products Company
Segment Reporting Information [Line Items]
Percentage of ownership interest	50%	50%	50%	50%
ArmaKleen Company
Segment Reporting Information [Line Items]
Percentage of ownership interest	50%	50%	50%	50%
Armand Products Company and ArmaKleen Company
Segment Reporting Information [Line Items]
Equity in earnings of affiliates	$ 3.7	$ 2	$ 10	$ 7.4

Selected Financial Information

Selected Financial Information Relating To Company's Segments (Details) - USD ($) $ in Millions		3 Months Ended			9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021		Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Net Sales		$ 1,317.3	$ 1,311.4		$ 3,939.6	$ 3,821.4
Income before Income Taxes		234.5	289.3		747.2	867.6
Operating Segments
Segment Reporting Information [Line Items]
Net Sales	[1]	1,317.3	1,311.4		3,939.6	3,821.4
Income before Income Taxes	[2]	234.5	289.3	[3]	747.2	867.6	[3]
Operating Segments | Consumer Domestic
Segment Reporting Information [Line Items]
Net Sales	[1]	1,010.4	998.1		3,010.2	2,900.2
Income before Income Taxes	[2]	193.9	238.6	[3]	618.3	713.7	[3]
Operating Segments | Consumer International
Segment Reporting Information [Line Items]
Net Sales	[1]	219.7	227		664.8	670.2
Income before Income Taxes	[2]	22.7	34.5	[3]	80.8	110.9	[3]
Operating Segments | Specialty Products
Segment Reporting Information [Line Items]
Net Sales	[1]	87.2	86.3		264.6	251
Income before Income Taxes	[2]	14.2	14.2	[3]	38.1	35.6	[3]
Corporate
Segment Reporting Information [Line Items]
Net Sales	[1],[4]	0	0		0	0
Income before Income Taxes	[2],[4]	$ 3.7	$ 2	[3]	$ 10	$ 7.4	[3]
[1] Intersegment sales from Consumer International to Consumer Domestic, which are not reflected in the table, were $ 3.9 and $ 2.6 for the three months ended September 30, 2022 and September 30, 2021, respectively, and were $ 12.5 and $ 7.8 for the nine months ended September 30, 2022 and September 30, 2021, respectively. In determining income before income taxes, interest expense, investment earnings and certain aspects of other income and expense were allocated among segments based upon each segment’s relative income from operations. Results for the three months ended September 30, 2021 include a $ 41.0 reduction of SG&A expenses to adjust the Flawless business acquisition liability, of which $ 34.8 was recorded to Consumer Domestic and $ 6.2 was recorded to Consumer International. Results for the nine months ended September 30, 2021 include a $ 98.0 reduction of SG&A expenses to adjust the Flawless business acquisition liability, of which $ 83.2 was recorded to Consumer Domestic and $ 14.8 was recorded to Consumer International. The Corporate segment consists of equity in earnings of affiliates from Armand and ArmaKleen for the three and nine months ended September 30, 2022 and September 30, 2021.

Selected Financial Informatio_2

Selected Financial Information Relating To Company's Segments (Parenthetical) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Net Sales	$ 1,317.3	$ 1,311.4	$ 3,939.6	$ 3,821.4
Selling General and Administrative Expenses
Segment Reporting Information [Line Items]
Increase (decrease) in expenses		41		98
Flawless Acquisition | Consumer Domestic
Segment Reporting Information [Line Items]
Increase (decrease) in estimate of contingent consideration liability		34.8		83.2
Flawless Acquisition | Consumer International
Segment Reporting Information [Line Items]
Increase (decrease) in estimate of contingent consideration liability		6.2		14.8
Intersegment Sales
Segment Reporting Information [Line Items]
Net Sales	$ 3.9	$ 2.6	$ 12.5	$ 7.8

Product Line Revenues from Exte

Product Line Revenues from External Customers (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment Reporting Information [Line Items]
Net Sales		$ 1,317.3	$ 1,311.4	$ 3,939.6	$ 3,821.4
Operating Segments
Segment Reporting Information [Line Items]
Net Sales	[1]	1,317.3	1,311.4	3,939.6	3,821.4
Operating Segments | Consumer Domestic
Segment Reporting Information [Line Items]
Net Sales	[1]	1,010.4	998.1	3,010.2	2,900.2
Operating Segments | Consumer Domestic | Household Products
Segment Reporting Information [Line Items]
Net Sales		592.3	535.5	1,685.6	1,553.7
Operating Segments | Consumer Domestic | Personal Care Products
Segment Reporting Information [Line Items]
Net Sales		418.1	462.6	1,324.6	1,346.5
Operating Segments | Consumer International
Segment Reporting Information [Line Items]
Net Sales	[1]	219.7	227	664.8	670.2
Operating Segments | Specialty Products
Segment Reporting Information [Line Items]
Net Sales	[1]	$ 87.2	$ 86.3	$ 264.6	$ 251
[1] Intersegment sales from Consumer International to Consumer Domestic, which are not reflected in the table, were $ 3.9 and $ 2.6 for the three months ended September 30, 2022 and September 30, 2021, respectively, and were $ 12.5 and $ 7.8 for the nine months ended September 30, 2022 and September 30, 2021, respectively.

Subsequent Event (Additional In

Subsequent Event (Additional Information) (Details) - USD ($) $ in Millions	Aug. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Restricted shares of the company's common stock		$ 292.8	$ 292.8
Hero Acquisition [Member]
Subsequent Event [Line Items]
Purchase Price Held Back For Indemnification Obligations	$ 8
Restricted shares of the company's common stock	65
Acquisition Cost	$ 565

Subsequent Event - Summary of f

Subsequent Event - Summary of fair values of the net assets at acquisition (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Goodwill	$ 2,270.7	$ 2,274.5